Sign in
NUGX Stock Price, Chart, Stats & News
NuGenerex Immuno-Oncology, Inc.
Save
NuGenerex Immuno-Oncology, Inc. (NUGX) does not currently pay a dividend.
10,030
Market cap
–
Current P/E
–
Forward P/E
NUGX chart
1M
3M
1Y
5Y
Loading chart...
About
Health care
Sector
Biotechnology
Industry
NuGenerex Immuno-Oncology, Inc. is an oncology firm committed to treating cancer through the strategic modulation of the immune system. The company's development pipeline includes a range of immunotherapeutic products and vaccines. Notably, it is advancing AE37, a peptide immunotherapeutic vaccine, which is currently undergoing Phase II clinical studies for metastatic triple-negative breast cancer.
Similar securities
Based on sector and market capitalization
Report issue